Johnson & Johnson Derivative Instruments in Hedges, Assets, at Fair Value
Johnson & Johnson (JNJ) had Derivative Instruments in Hedges, Assets, at Fair Value of $1.32 billion as of 2026-06-28, per its 10-Q filed 2026-07-23.
Financial Statements › Notes › Derivative Instruments in Hedges, at Fair Value, Net
us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue · last filed 2026-07-23
- 2026-06-28: Derivative Instruments in Hedges, Assets, at Fair Value $1.32B.
- 2026-03-29: Derivative Instruments in Hedges, Assets, at Fair Value $1.16B.
- 2025-12-28: Derivative Instruments in Hedges, Assets, at Fair Value $1.27B.
- 2025-09-28: Derivative Instruments in Hedges, Assets, at Fair Value $1.40B.
| Period end | Derivative Instruments in Hedges, Assets, at Fair Value |
|---|---|
| 2026-06-28 | $1.32B 10-Q · filed 2026-07-23 |
| 2026-03-29 | $1.16B 10-Q · filed 2026-04-22 |
| 2025-12-28 | $1.27B 10-K · filed 2026-02-11 |
| 2025-09-28 | $1.40B 10-Q · filed 2025-10-22 |
| 2025-06-29 | $1.44B 10-Q · filed 2025-07-24 |
| 2025-03-30 | $1.67B 10-Q · filed 2025-04-23 |
| 2024-12-29 | $2.14B 10-K · filed 2025-02-13 |
| 2024-09-29 | $1.46B 10-Q · filed 2024-10-23 |
| 2024-06-30 | $1.92B 10-Q · filed 2024-07-25 |
| 2024-03-31 | $1.70B 10-Q · filed 2024-05-01 |
| 2023-12-31 | $1.53B 10-K · filed 2024-02-16 |
| 2023-10-01 | $2.44B 10-Q · filed 2023-10-27 |
| 2023-07-02 | $2.20B 10-Q · filed 2023-07-31 |
| 2023-04-02 | $2.06B 10-Q · filed 2023-04-28 |
| 2023-01-01 | $2.16B 10-K · filed 2023-02-16 |
| 2022-10-02 | $4.47B 10-Q · filed 2022-10-27 |
| 2022-07-03 | $3.29B 10-Q · filed 2022-07-29 |
| 2022-04-03 | $1.72B 10-Q · filed 2022-04-29 |
| 2022-01-02 | $1.34B 10-K · filed 2022-02-17 |
| 2021-10-03 | $1.17B 10-Q · filed 2021-10-29 |
| 2021-07-04 | $856.00M 10-Q · filed 2021-07-29 |
| 2021-04-04 | $1.08B 10-Q · filed 2021-04-30 |
| 2021-01-03 | $1.09B 10-K · filed 2021-02-22 |
| 2020-09-27 | $1.25B 10-Q · filed 2020-10-23 |
| 2020-06-28 | $1.52B 10-Q · filed 2020-07-24 |
| 2020-03-29 | $2.51B 10-Q · filed 2020-04-29 |
| 2019-12-29 | $902.00M 10-K · filed 2020-02-18 |
| 2019-09-29 | $1.18B 10-Q · filed 2019-10-28 |
| 2019-06-30 | $576.00M 10-Q · filed 2019-07-29 |
| 2019-03-31 | $663.00M 10-Q · filed 2019-05-01 |
| 2018-09-30 | $570.00M 10-Q · filed 2018-10-31 |
| 2018-07-01 | $593.00M 10-Q · filed 2018-08-02 |
| 2018-04-01 | $354.00M 10-Q · filed 2018-05-01 |
| 2017-10-01 | $572.00M 10-Q · filed 2017-11-02 |
| 2017-07-02 | $433.00M 10-Q · filed 2017-08-03 |
| 2017-04-02 | $320.00M 10-Q · filed 2017-05-08 |
| 2016-10-02 | $272.00M 10-Q · filed 2016-11-04 |
| 2016-07-03 | $334.00M 10-Q · filed 2016-08-04 |
| 2016-04-03 | $369.00M 10-Q · filed 2016-05-10 |
| 2016-01-03 | $480.00M 10-K · filed 2016-02-24 |
| 2015-09-27 | $842.00M 10-Q · filed 2015-10-30 |
| 2015-06-28 | $760.00M 10-Q · filed 2015-07-31 |
| 2015-03-29 | $1.03B 10-Q · filed 2015-05-01 |
| 2014-12-28 | $1.03B 10-K · filed 2015-02-24 |
| 2014-09-28 | $645.00M 10-Q · filed 2014-10-30 |
| 2014-06-29 | $404.00M 10-Q · filed 2014-08-01 |
| 2014-03-30 | $642.00M 10-Q · filed 2014-05-02 |
| 2013-12-29 | $706.00M 10-K · filed 2014-02-21 |
| 2013-09-29 | $609.00M 10-Q · filed 2013-11-04 |
| 2013-06-30 | $752.00M 10-Q · filed 2013-08-01 |
| 2013-03-31 | $492.00M 10-Q · filed 2013-05-03 |
| 2012-12-30 | $521.00M 10-K · filed 2013-02-22 |
| 2012-09-30 | $222.00M 10-Q · filed 2012-11-09 |
| 2012-07-01 | $466.00M 10-Q · filed 2012-08-02 |
| 2012-04-01 | $249.00M 10-Q · filed 2012-05-07 |
| 2012-01-01 | $457.00M 10-K · filed 2012-02-23 |
| 2011-10-02 | $611.00M 10-Q · filed 2011-11-08 |
| 2011-07-03 | $489.00M 10-Q · filed 2011-08-09 |
| 2011-04-03 | $467.00M 10-Q · filed 2011-05-10 |
| 2011-01-02 | $338.00M 10-K · filed 2012-02-23 |
| 2010-10-03 | $396.00M 10-Q · filed 2010-11-10 |
| 2010-07-04 | $417.00M 10-Q · filed 2010-08-11 |
| 2010-01-03 | $562.00M 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |